|Articles|November 2, 2021

Pharmaceutical Technology

  • Pharmaceutical Technology, November 2021 Issue
  • Volume 45
  • Issue 11

Practical SPC Rules in the Real World of an Ongoing Process Verification Plan: Part 2. Practical SPC Rules to Apply on Pharmaceutical Process Data

Author(s)Raphael Bar

Part two of this article series shows how traditional statistical process control rules can be relaxed or adjusted to allow charting and evaluation of real-life data of pharmaceutical processes with a reduced number of false alarms.

Part two of this article series shows how traditional statistical process control rules can be relaxed or adjusted to allow charting and evaluation of real-life data of pharmaceutical processes with a reduced number of false alarms. Ten practical tools or measures are suggested for minimizing false alarms among process data plotted as is on charts, provided concurrent process performance and product quality are demonstrated. This pragmatic approach reduces the number of futile investigations of apparent innocuous process deviations and streamlines the implementation of the third process validation stage of continued process verification or ongoing process verification.

Click here for a PDF of the article.

Click here for a PDF of the article.

Peer-Reviewed

Submitted: March 3, 2021
Accepted: May 3, 2021

About the Author

Raphael Bar, PhD, [email protected], is a consultant at BR Consulting in Ness Ziona, Israel.

Article Details

Pharmaceutical Technology
Volume 45, Number 11
November 2021
Pages: 46–53

Citation

When referring to this article, please cite it as R. Bar, “Practical SPC Rules in the Real World of an Ongoing Process Verification Plan: Part 2. Practical SPC Rules to Apply on Pharmaceutical Process,” Pharmaceutical Technology 45 (11) 2021.


Related to this article

Intravenous therapy; drip chamber in focus against a colorful background | Image Credit: ©Anna Jurkovska -stock.adobe.com
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.